A Phase 3 interventional study of TSND-201 in Post Traumatic Stress Disorder, sponsored by Transcend Therapeutics. Enrolling by invitation at 17 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Transcend Therapeutics (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd. — 3 open to participants now, 3 under way, 3 of them phase 3. Stress Disorders, Post-Traumatic · Otsuka Holdings Co., Ltd..
Among the 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd., this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 3, and was the 10th registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →3 of the 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Transcend Therapeutics · Sites in United States
Ages 18+
Transcend Therapeutics · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5
First in 2017; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 69 across 2,199 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 300 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Transcend Therapeutics, one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Transcend Therapeutics is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Stress Disorders, Post-Traumatic by Otsuka Holdings Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical trial with TNSD-201 for PTSD will be invited to participate in this open-label extension trial.
Each participant will be able to receive up to three Treatment Courses over the duration of the study (up to 48 weeks). Each Treatment Course includes 4 dosing sessions, spaced one week apart.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: TSND-201
TSND-201 capsules, given orally; where a course of treatment includes dosing with TSND-201 once a week for four consecutive weeks
Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score
CAPS-5 is a structured interview designed to assess PTSD symptoms severity. The total severity score ranges from 0 to 80, with a higher score indicating more severe symptoms.
Time frame: Up to 48 weeks
Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.
Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 30 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TSND-201
Stress Disorders, Post-Traumatic →